GlassScriptPhysician profile
Richard Anthony Ozog
NPI 1144278367
$1,577.42
in general payments reported to CMS, 2019-2025
26 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $100 · 2021: $155 · 2022: $272 · 2023: $440 · 2024: $252 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $298.13 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $179.54 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Astrazeneca Pharmaceuticals LP | $171.09 | 2024 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $163.02 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $144.99 | 2021-2025 | |
| Amgen INC. | $108.21 | 2021-2025 | Krystexxa, Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $79.94 | 2019 | |
| Abbott Laboratories | $71.30 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.89 | 2023 | Jardiance |
| Novo Nordisk INC | $28.52 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $23.36 | 2023 | Hetlioz |
| Medtronic, INC. | $22.76 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.64 | 2023 | Voquezna |
| Novartis Pharmaceuticals Corporation | $21.22 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.18 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $18.44 | 2020 | |
| Genentech USA, INC. | $16.66 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.40 | 2022 | |
| Lilly USA, LLC | $15.05 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.97 | 2025 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $14.66 | 2019 | |
| Allergan, INC. | $14.56 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2019 | |
| Merck Sharp & Dohme LLC | $12.98 | 2021 | |
| Lundbeck LLC | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ozog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.